Aakash Nathani
Overview
Explore the profile of Aakash Nathani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nathani A, Khan I, Tanimoto M, Mejia J, DE Miranda A, Rishi A, et al.
Anticancer Res
. 2024 Sep;
44(10):4175-4188.
PMID: 39348999
Background/aim: Low selectivity and high frequency of side-effects are the major problems of currently used chemotherapeutics. Among natural compounds, the polyprenylated acylphloroglucinol, guttiferone E, isolated from Brazilian red propolis, has...
2.
Nathani A, Aare M, Sun L, Bagde A, Li Y, Rishi A, et al.
Pharmaceutics
. 2024 Aug;
16(8.
PMID: 39204415
This study investigates the use of camel milk-derived exosomes (CMEs) as carriers for ARV-825, an anticancer agent targeting bromodomain-containing protein 4 (BRD4), in oral chemotherapy. CMEs were isolated and characterized,...
3.
Aare M, Bagde A, Nathani A, Rishi A, Singh M
Int J Pharm
. 2024 Jun;
663:124375.
PMID: 38914353
The potential of camel milk-derived exosomes (CMDE) to enhance the bioavailability of Cannabidiol (CBD) was investigated. CBD-CMDE formulation was prepared using an established procedure and its particle size was 138.4 ...
4.
Berry D, Ene J, Nathani A, Singh M, Li Y, Zeng C
Biomedicines
. 2024 Mar;
12(3.
PMID: 38540102
The peripheral nervous system undergoes sufficient stress when affected by diabetic conditions, chemotherapeutic drugs, and personal injury. Consequently, peripheral neuropathy arises as the most common complication, leading to debilitating symptoms...
5.
Nathani A, Sun L, Khan I, Aare M, Bagde A, Li Y, et al.
Pharmaceutics
. 2024 Jan;
16(1).
PMID: 38258094
In this study, we evaluated IL-15 stimulated natural killer cell-derived EVs (NK-EVs) as therapeutic agents in vitro and in vivo in Osimertinib-resistant lung cancer (H1975R) with EGFR mutations (L858R) in...
6.
Kaur S, Nathani A, Singh M
Cancer Lett
. 2023 May;
566:216243.
PMID: 37257632
Exosomes are extracellular vesicles (EVs) originating from endosomes that play a role in cellular communication. These vesicles which mimic the parental cells that release them are promising candidates for targeted...
7.
Bagde A, Dev S, Madhavi K Sriram L, Spencer S, Kalvala A, Nathani A, et al.
Int J Pharm
. 2023 Feb;
636:122647.
PMID: 36754185
The objective of the present study was to fabricate microneedles for delivering lipophilic active ingredients (APIs) using digital light processing (DLP) printing technology and quality by design (QbD) supplemented by...
8.
Kalvala A, Nimma R, Bagde A, Surapaneni S, Patel N, Arthur P, et al.
Biochimie
. 2022 Dec;
208:19-30.
PMID: 36535544
The significant resistance to currently available chemotherapeutics makes treatment for TNBC a key clinical concern. Herein, we studied the anti-cancer potentials of synthetic cannabidiol (CBD) and Tetrahydrocannabivarin (THCV) when used...
9.
Arthur P, Muok L, Nathani A, Zeng E, Sun L, Li Y, et al.
Cells
. 2022 Nov;
11(21).
PMID: 36359825
Retinal organoids are three-dimensional (3D) structures derived from human pluripotent stem cells (hPSCs) that mimic the retina's spatial and temporal differentiation, making them useful as in vitro retinal development models....
10.
Nimma R, Kalvala A, Patel N, Surapaneni S, Sun L, Singh R, et al.
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745729
The epidermal growth factor receptor (EGFR) is highly expressed in many non-small cell lung cancers (NSCLC), necessitating the use of EGFR-tyrosine kinase inhibitors (TKIs) as first-line treatments. Osimertinib (OSM), a...